Compare DexCom, Inc. (DXCM) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JetBlue Airways Corporation — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while JetBlue Airways Corporation trades at $5.62 (market cap $2.07B). The key difference: DexCom, Inc. is far larger — about 13.6× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| DXCM | JBLU | |
|---|---|---|
Market Cap | $28.06B | $2.07B |
Sector | Health | Industrials |
52-Week High | $89.53 | $6.46 |
52-Week Low | $54.84 | $4.03 |
Enterprise Value | $27.03B | $9.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
JetBlue (JBLU) trades at $5.33, down 4.82% over 24 hours, with a mixed technical signal showing bullish moving averages but neutral oscillators. The company reported a net loss of $602 million in 2025, with negative profit margins and elevated debt levels. Recent news highlights expansion at Fort Lauderdale and a new payment partnership with ClarityPay, while Q2 2026 earnings are anticipated on July 28, 2026.
The outlook remains challenging due to persistent losses and high leverage, though cost initiatives and strategic expansions offer potential upside. Risks include fuel price volatility and competitive pressures, while analyst consensus is mostly hold with a $5.12 price target, suggesting limited near-term optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
